TMTPOST — AI biotechnology startup EonArk completed seed and seed+ financing rounds totaling nearly 100 million yuan ($14 million) within one month. Monolith, Boyu Capital, and Nine Chapters Capital participated in the seed round, with Nine Chapters Capital leading the seed+ round alongside continued investment from Monolith and Boyu Capital, plus new participant Starlink Capital. The funds will support research advancement and team expansion. Founder and CEO Si Zhao, who holds a PhD in AI for medicine from Oxford University, leads the company’s long-term strategy and development of its longevity virtual cell platform. Investor interest in AI-native biotechnology platforms remains robust on the Chinese mainland, as corporate and venture capital backers look for breakthroughs at the intersection of artificial intelligence and life sciences. EonArk’s rapid funding success underscores growing confidence in founder-led teams with strong scientific pedigrees capable of building specialized models for complex biological challenges.